Pathological Response in a Triple Negative Breast Cancer Cohort Treated With Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-1912